Circulating mutational portrait of cancer: Manifestation of aggressive clonal events in both early and late stages

Journal of Hematology and Oncology

Volumn 10, Issue 1, 2017, Pages

  Yang, Meng ^a,b,d   Topaloglu, Umit ^a,b   Petty, W Jeffrey ^a,b   Pagni, Matthew ^a,b   Foley, Kristie L ^a,b   Grant, Stefan C ^a,b   Robinson, Mac ^a,b   Bitting, Rhonda L ^a,b   Thomas, Alexandra ^a,b   Alistar, Angela T ^a,b   Desnoyers, Rodwige J ^a,b   Goodman, Michael ^a,b   Albright, Carol ^a,b   Porosnicu, Mercedes ^a,b   Vatca, Mihaela ^a,b   Qasem, Shadi A ^a,b   Deyoung, Barry ^a,b   Kytola, Ville ^a,b,c   Nykter, Matti ^c   Chen, Kexin ^d   Levine, Edward A ^a,b   Staren, Edgar D ^a,b   D'Agostino, Ralph B ^a,b   Petro, Robin M ^a,b   Blackstock, William ^a,b   Powell, Bayard L ^a,b   Abraham, Edward ^a,b   Pasche, Boris ^a,b   Zhang, Wei ^a,b   more..

^a WAKE FOREST BAPTIST HEALTH   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^d TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Clonality; Liquid biopsy; Lung cancer; Mutation rate; Non invasive

Indexed keywords

ATM PROTEIN; CHLOROPLAST DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; K RAS PROTEIN; PROTEIN P53; ANTINEOPLASTIC AGENT; DNA; EGFR PROTEIN, HUMAN; ERLOTINIB; PROTEIN KINASE INHIBITOR; TUMOR PROTEIN;

ADULT; AGED; ARTICLE; ATM GENE; CANCER GROWTH; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; DNA ISOLATION; DNA REPAIR; EARLY CANCER; EGFR GENE; ERBB2 GENE; FEMALE; GENE SEQUENCE; GENETIC ASSOCIATION; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASM; MOLECULAR DIAGNOSIS; MUTATION RATE; MUTATIONAL ANALYSIS; ONCOGENE K RAS; PATIENT MONITORING; TP53 GENE; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE; ANTAGONISTS AND INHIBITORS; CANCER STEM CELL; CELL CLONE; CHEMORADIOTHERAPY; DISEASE EXACERBATION; DNA SEQUENCE; GENE EXPRESSION PROFILING; GENETICS; LUNG TUMOR; MIDDLE AGED; MORTALITY; MUTATION; NEOPLASM; ONCOGENE RAS; PATHOLOGY; PROTO ONCOGENE; RETROSPECTIVE STUDY; SMOKING; TUMOR EMBOLISM; TUMOR GENE; TUMOR INVASION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CHEMORADIOTHERAPY; CLONE CELLS; DISEASE PROGRESSION; DNA, NEOPLASM; ERLOTINIB HYDROCHLORIDE; FEMALE; GENE EXPRESSION PROFILING; GENES, ERBB-1; GENES, NEOPLASM; GENES, P53; GENES, RAS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; NEOPLASMS; NEOPLASTIC CELLS, CIRCULATING; NEOPLASTIC STEM CELLS; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; SEQUENCE ANALYSIS, DNA; SMOKING;

EID: 85018772071     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/s13045-017-0468-1     Document Type: Article

References (60)

1. Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014;511(7511):543-50.
2. Davis JN, et al. Association of core-binding factor beta with the malignant phenotype of prostate and ovarian cancer cells. J Cell Physiol. 2010;225(3):875-87.
3. Tulinius H, et al. The effect of a single BRCA2 mutation on cancer in Iceland. J Med Genet. 2002;39(7):457-62.
4. Yoruker EE, Holdenrieder S, Gezer U. Blood-based biomarkers for diagnosis, prognosis and treatment of colorectal cancer. Clin Chim Acta. 2016;455:26-32.
5. Jiang T, Ren S, Zhou C. Role of circulating-tumor DNA analysis in non-small cell lung cancer. Lung Cancer. 2015;90(2):128-34.
6. De Mattos-Arruda L, Caldas C. Cell-free circulating tumour DNA as a liquid biopsy in breast cancer. Mol Oncol. 2016;10(3):464-74.
7. Kim ST, et al. Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients. Oncotarget. 2015;6(37):40360-9.
8. Bettegowda C, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6(224):224ra24.
9. Yanagita M, et al. A prospective evaluation of circulating tumor cells and cell-free DNA in EGFR-mutant non-small cell lung cancer patients treated with erlotinib on a phase ii trial. Clin Cancer Res. 2016;22(24):6010-20.
10. Uchida J, et al. Diagnostic accuracy of noninvasive genotyping of EGFR in lung cancer patients by deep sequencing of plasma cell-free DNA. Clin Chem. 2015;61(9):1191-6.
11. Wang HY, et al. Cancers screening in an asymptomatic population by using multiple tumour markers. PLoS One. 2016;11(6):e0158285.
12. Leong SM, et al. Sampling circulating tumor cells for clinical benefits: how frequent? J Hematol Oncol. 2015;8:75.
13. He CZ, et al. Combined use of AFP, CEA, CA125 and CAl9-9 improves the sensitivity for the diagnosis of gastric cancer. BMC Gastroenterol. 2013;13:87.
14. Zhu CS, et al. A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer. Cancer Prev Res (Phila). 2011;4(3):375-83.
15. Kirwan A, et al. Glycosylation-based serum biomarkers for cancer diagnostics and prognostics. Biomed Res Int. 2015;2015:490531.
16. Dai H, et al. Increased lung cancer risk in patients with interstitial lung disease and elevated CEA and CA125 serum tumour markers. Respirology. 2014;19(5):707-13.
17. Diehl F, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008;14(9):985-90.
18. Chae YK, et al. Concordance between genomic alterations assessed by next-generation sequencing in tumor tissue or circulating cell-free DNA. Oncotarget. 2016;7(40):65364-73.
19. Jovelet C, et al. Circulating cell-free tumor DNA analysis of 50 Genes by next-generation sequencing in the prospective MOSCATO trial. Clin Cancer Res. 2016;22(12):2960-8.
20. Esposito A, et al. Monitoring tumor-derived cell-free DNA in patients with solid tumors: clinical perspectives and research opportunities. Cancer Treat Rev. 2014;40(5):648-55.
21. Dawson SJ, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med. 2013;368(13):1199-209.
22. Schwaederle M, et al. Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay. Oncotarget. 2016;7(9):9707-17.
23. Pixberg CF, et al. Analysis of DNA methylation in single circulating tumor cells. Oncogene. 2017. doi: 10.1038/onc.2016.480.
24. Mitchell SM, et al. Evaluation of methylation biomarkers for detection of circulating tumor dna and application to colorectal cancer. Genes (Basel). 2016;7:12.
25. Fackler MJ, et al. Novel methylated biomarkers and a robust assay to detect circulating tumor DNA in metastatic breast cancer. Cancer Res. 2014;74(8):2160-70.
26. Shaw JA, et al. Mutation analysis of cell-free DNA and single circulating tumor cells in metastatic breast cancer patients with high circulating tumor cell counts. Clin Cancer Res. 2017;23(1):88-96.
27. Park SM, et al. Molecular profiling of single circulating tumor cells from lung cancer patients. Proc Natl Acad Sci U S A. 2016;113(52):E8379-86.
28. Canzoniero JV, Park BH. Use of cell free DNA in breast oncology. Biochim Biophys Acta. 2016;1865(2):266-74.
29. Ocana A, et al. Circulating DNA and survival in solid tumors. Cancer Epidemiol Biomarkers Prev. 2016;25(2):399-406.
30. Ai B, et al. Circulating cell-free DNA as a prognostic and predictive biomarker in non-small cell lung cancer. Oncotarget. 2016;7(28):44583-95.
31. La Vecchia C, et al. Time since stopping smoking and the risk of oral and pharyngeal cancers. J Natl Cancer Inst. 1999;91(8):726-8.
32. Lanman RB, et al. Analytical and clinical validation of a digital sequencing panel for quantitative, highly accurate evaluation of cell-free circulating tumor DNA. PLoS One. 2015;10(10):e0140712.
33. Frampton GM, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol. 2013;31(11):1023-31.
34. Wu P, et al. Causal inference for Mann-Whitney-Wilcoxon rank sum and other nonparametric statistics. Stat Med. 2014;33(8):1261-71.
35. Nahm FS. Nonparametric statistical tests for the continuous data: the basic concept and the practical use. Korean J Anesthesiol. 2016;69(1):8-14.
36. Miller CA, et al. SciClone: inferring clonal architecture and tracking the spatial and temporal patterns of tumor evolution. PLoS Comput Biol. 2014;10(8):e1003665.
37. Thompson JC, et al. Detection of therapeutically targetable driver and resistance mutations in lung cancer patients by next-generation sequencing of cell-free circulating tumor DNA. Clin Cancer Res. 2016;22(23):5772-82.
38. Villaflor V, et al. Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer. Oncotarget. 2016;7(41):66880-91.
39. Scaltriti M, Baselga J. The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res. 2006;12(18):5268-72.
40. Calvo E, Rowinsky EK. Effect of epidermal growth factor receptor mutations on the response to epidermal growth factor receptor tyrosine kinase inhibitors: target-based populations for target-based drugs. Clin Lung Cancer. 2004;6 Suppl 1:S35-42.
41. Sequist LV, et al. Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing. Oncologist. 2007;12(1):90-8.
42. Kim YH, et al. EGFR mutation: Significance as a stratification factor in the era of molecular-targeted therapy. Oncol Lett. 2011;2(2):383-7.
43. Kris MG, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA. 2003;290(16):2149-58.
44. Paez JG, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304(5676):1497-500.
45. Lynch TJ, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350(21):2129-39.
46. Sequist LV, et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol. 2008;26(15):2442-9.
47. Perez-Soler R, et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol. 2004;22(16):3238-47.
48. Remon J, et al. Osimertinib benefit in EGFR-mutant NSCLC patients with T790M-mutation detected by circulating tumour DNA. Ann Oncol. 2017;28(4):784-90.
49. Yang D, et al. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA. 2011;306(14):1557-65.
50. Chen K, et al. Mutational landscape of gastric adenocarcinoma in Chinese: implications for prognosis and therapy. Proc Natl Acad Sci U S A. 2015;112(4):1107-12.
51. Heidorn SJ, et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell. 2010;140(2):209-21.
52. Sen B, et al. Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib. Sci Transl Med. 2012;4(136):136ra70.
53. Solit DB, et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature. 2006;439(7074):358-62.
54. Bai C, et al. A novel PDGFRA mutation in gastrointestinal stromal tumours, L839P, is sensitive to imatinib in vitro. Oncol Lett. 2012;3(5):1139-43.
55. McDermott U, et al. Ligand-dependent platelet-derived growth factor receptor (PDGFR)-alpha activation sensitizes rare lung cancer and sarcoma cells to PDGFR kinase inhibitors. Cancer Res. 2009;69(9):3937-46.
56. Holtkamp N, et al. Mutation and expression of PDGFRA and KIT in malignant peripheral nerve sheath tumors, and its implications for imatinib sensitivity. Carcinogenesis. 2006;27(3):664-71.
57. Miller RE, et al. Synthetic lethal targeting of ARID1A-mutant ovarian clear cell tumors with dasatinib. Mol Cancer Ther. 2016;15(7):1472-84.
58. Mok TS, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med. 2017;376(7):629-40.
59. Chang GC, et al. Predictive factors for EGFR-tyrosine kinase inhibitor retreatment in patients with EGFR-mutated non-small-cell lung cancer - a multicenter retrospective SEQUENCE study. Lung Cancer. 2017;104:58-64.
60. Sun W, et al. Non-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancer. J Hematol Oncol. 2015;8:95.